Oxford BioTherapeutics Appoints Michael Moore as Chairman

10-Dec-2009 - United Kingdom

Oxford BioTherapeutics (OBT) has announced the appointment of Dr Michael Moore as non-executive Chairman.

Dr Moore has several decades of senior management experience in the biotechnology sector and joins the Board of OBT following five years at UK biotechnology company, Piramed Limited, where he was CEO until its acquisition by Roche in 2008. Prior to joining Piramed, Dr Moore was CSO and Research Director of Xenova Group plc. During a distinguished career he has also held senior academic positions at the Paterson Institute for Cancer Research, Christie Hospital, Manchester, UK and the Brunel Institute of Cancer Genetics and Pharmacogenomics where he is still Professor Associate.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances